ozenoxacin (Xepi)
Jump to navigation
Jump to search
Indications
- treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in adults or children >= 2 years
Dosage
- apply a thin layer topically to affected area q12hr for 5 days
- not to exceed 100 cm2 area in adults & adolescents or 2% of body surface area for children age 2 months to 12 years
Cream: 1%
Mechanism of action
- quinolone antimicrobial
- inhibits bacterial DNA replication enzymes, DNA gyrase A, & topoisomerase IV
More general terms
References
- ↑ Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Gropper S, Albareda N, Chelius K et al Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiol. 2014;9(9):1013-23. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25340832
Gropper S, Cepero AL, Santos B, Kruger D. Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo. Future Microbiol. 2014;9(8 Suppl):S33-40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25209523
Gropper S, Albareda N, Santos B, Febbraro S. Skin tissue exposure of once- versus twice-daily topical ozenoxacin 2% cream: a Phase I study in healthy volunteers. Future Microbiol. 2014;9(8 Suppl):S17-22. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25209520
Gropper S, Albareda N, Santos B, Febbraro S. Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers. Future Microbiol. 2014;9(8 Suppl):S11-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/5209519
Gropper S, Cepero AL, Dosik JS et al Cumulative irritation, sensitizing potential, phototoxicity and photoallergy of ozenoxacin in healthy adult volunteers. Future Microbiol. 2014;9(8 Suppl):S23-31. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25209521
Santos B, Ortiz J, Gropper S. In vitro percutaneous absorption and metabolism of ozenoxacin in excised human skin. Future Microbiol. 2014;9(8 Suppl):S3-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25209522